vs
CREDIT ACCEPTANCE CORP（CACC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是CREDIT ACCEPTANCE CORP的1.1倍（$622.0M vs $579.9M），Royalty Pharma plc净利率更高（34.4% vs 21.0%，领先13.4%），Royalty Pharma plc同比增速更快（4.8% vs 2.5%），过去两年CREDIT ACCEPTANCE CORP的营收复合增速更高（6.8% vs 4.6%）
Credit Acceptance是一家汽车金融服务提供商，主要提供汽车贷款及相关金融产品。公司通过覆盖全国的合作汽车经销商网络开展业务，设有“投资组合计划”和“采购计划”两大业务项目，可向汽车经销商提供资金，以此换取对应消费者贷款的后续服务权利。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CACC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.1倍
$579.9M
营收增速更快
RPRX
高出2.3%
2.5%
净利率更高
RPRX
高出13.4%
21.0%
两年增速更快
CACC
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $579.9M | $622.0M |
| 净利润 | $122.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 27.1% | 62.4% |
| 净利率 | 21.0% | 34.4% |
| 营收同比 | 2.5% | 4.8% |
| 净利润同比 | -19.7% | 2.9% |
| 每股收益（稀释后） | $10.87 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CACCRPRX
| Q4 25 | $579.9M | $622.0M | ||
| Q3 25 | $582.4M | $609.3M | ||
| Q2 25 | $583.8M | $578.7M | ||
| Q1 25 | $571.1M | $568.2M | ||
| Q4 24 | $565.9M | $593.6M | ||
| Q3 24 | $550.3M | $564.7M | ||
| Q2 24 | $538.2M | $537.3M | ||
| Q1 24 | $508.0M | $568.0M |
净利润CACCRPRX
| Q4 25 | $122.0M | $214.2M | ||
| Q3 25 | $108.2M | $288.2M | ||
| Q2 25 | $87.4M | $30.2M | ||
| Q1 25 | $106.3M | $238.3M | ||
| Q4 24 | $151.9M | $208.2M | ||
| Q3 24 | $78.8M | $544.0M | ||
| Q2 24 | $-47.1M | $102.0M | ||
| Q1 24 | $64.3M | $4.8M |
营业利润率CACCRPRX
| Q4 25 | 27.1% | 62.4% | ||
| Q3 25 | 25.6% | 70.1% | ||
| Q2 25 | 20.2% | 36.3% | ||
| Q1 25 | 24.8% | 94.0% | ||
| Q4 24 | 33.9% | 60.9% | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | -10.3% | 50.2% | ||
| Q1 24 | 17.0% | -13.0% |
净利率CACCRPRX
| Q4 25 | 21.0% | 34.4% | ||
| Q3 25 | 18.6% | 47.3% | ||
| Q2 25 | 15.0% | 5.2% | ||
| Q1 25 | 18.6% | 41.9% | ||
| Q4 24 | 26.8% | 35.1% | ||
| Q3 24 | 14.3% | 96.3% | ||
| Q2 24 | -8.8% | 19.0% | ||
| Q1 24 | 12.7% | 0.8% |
每股收益（稀释后）CACCRPRX
| Q4 25 | $10.87 | $0.49 | ||
| Q3 25 | $9.43 | $0.67 | ||
| Q2 25 | $7.42 | $0.07 | ||
| Q1 25 | $8.66 | $0.55 | ||
| Q4 24 | $12.28 | $0.46 | ||
| Q3 24 | $6.35 | $1.21 | ||
| Q2 24 | $-3.83 | $0.23 | ||
| Q1 24 | $5.08 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.8M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.5B | $9.7B |
| 总资产 | $8.6B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CACCRPRX
| Q4 25 | $22.8M | $618.7M | ||
| Q3 25 | $15.9M | $938.9M | ||
| Q2 25 | $70.0M | $631.9M | ||
| Q1 25 | $528.8M | $1.1B | ||
| Q4 24 | $343.7M | $929.0M | ||
| Q3 24 | $159.7M | $950.1M | ||
| Q2 24 | $8.3M | $1.8B | ||
| Q1 24 | $8.4M | $843.0M |
总债务CACCRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CACCRPRX
| Q4 25 | $1.5B | $9.7B | ||
| Q3 25 | $1.6B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.7B | $9.8B | ||
| Q4 24 | $1.7B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.6B | $9.8B | ||
| Q1 24 | $1.7B | $9.9B |
总资产CACCRPRX
| Q4 25 | $8.6B | $19.6B | ||
| Q3 25 | $8.6B | $19.3B | ||
| Q2 25 | $8.7B | $18.3B | ||
| Q1 25 | $9.3B | $17.6B | ||
| Q4 24 | $8.9B | $18.2B | ||
| Q3 24 | $8.7B | $18.0B | ||
| Q2 24 | $8.3B | $17.7B | ||
| Q1 24 | $8.1B | $16.1B |
负债/权益比CACCRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $269.3M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $268.9M | — |
| 自由现金流率自由现金流/营收 | 46.4% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 2.21× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $1.1B | — |
8季度趋势，按日历期对齐
经营现金流CACCRPRX
| Q4 25 | $269.3M | $827.1M | ||
| Q3 25 | $299.4M | $702.6M | ||
| Q2 25 | $139.7M | $364.0M | ||
| Q1 25 | $346.2M | $596.1M | ||
| Q4 24 | $306.2M | $742.5M | ||
| Q3 24 | $317.7M | $703.6M | ||
| Q2 24 | $204.0M | $658.2M | ||
| Q1 24 | $310.0M | $664.6M |
自由现金流CACCRPRX
| Q4 25 | $268.9M | — | ||
| Q3 25 | $298.8M | — | ||
| Q2 25 | $139.4M | — | ||
| Q1 25 | $345.9M | — | ||
| Q4 24 | $305.5M | — | ||
| Q3 24 | $317.3M | — | ||
| Q2 24 | $203.6M | — | ||
| Q1 24 | $309.7M | — |
自由现金流率CACCRPRX
| Q4 25 | 46.4% | — | ||
| Q3 25 | 51.3% | — | ||
| Q2 25 | 23.9% | — | ||
| Q1 25 | 60.6% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 57.7% | — | ||
| Q2 24 | 37.8% | — | ||
| Q1 24 | 61.0% | — |
资本支出强度CACCRPRX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率CACCRPRX
| Q4 25 | 2.21× | 3.86× | ||
| Q3 25 | 2.77× | 2.44× | ||
| Q2 25 | 1.60× | 12.06× | ||
| Q1 25 | 3.26× | 2.50× | ||
| Q4 24 | 2.02× | 3.57× | ||
| Q3 24 | 4.03× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 4.82× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CACC
| Loans Receivable | $553.0M | 95% |
| Other | $26.9M | 5% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
